Litcius/Paper detail

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

Bruce Strober, Diamant Thaçi, Howard Sofen, Leon Kircik, Kenneth B. Gordon, Peter Foley, Phoebe Rich, C. Paul, Jerry Bagel, Elizabeth Colston, John Throup, Sudeep Kundu, Chitra Sekaran, Misti Linaberry, Subhashis Banerjee, Kim Papp

2022Journal of the American Academy of Dermatology279 citationsDOIOpen Access PDF

Topics & Concepts

ApremilastMedicinePsoriasisPlaceboAdverse effectPsoriasis Area and Severity IndexInternal medicineRandomized controlled trialGastroenterologyDermatology Life Quality IndexClinical trialDermatologyPsoriatic arthritisPathologyAlternative medicinePsoriasis: Treatment and PathogenesisSpondyloarthritis Studies and TreatmentsNF-κB Signaling Pathways
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial | Litcius